Navigation Links
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
Date:12/7/2011

WEDNESDAY, Dec. 7 (HealthDay News) -- In November, the U.S. Food and Drug Administration revoked its approval of the drug Avastin for the treatment of breast cancer. But, a new study suggests that the drug can boost the survival of women with a specific type of aggressive breast tumor when used in conjunction with two other medications.

Avastin (bevacizumab) had been approved in the United States in 2008 as a treatment for metastatic breast cancer -- cancer that has spread to other parts of the body. It was used with chemotherapy to treat a type of breast tumor called HER2-negative.

Even though the FDA withdrew that approval, Avastin is still approved to treat some other types of cancers. Doctors may legally prescribe the drug to treat breast cancer, although insurers may refuse to cover it.

According to the FDA, the benefits of Avastin use for breast cancer do not justify the risks, which may include severe high blood pressure, bleeding, and heart attack or heart failure.

The new study was funded by Genentech, which makes Avastin, and led by Dr. Luca Gianni, director of medical oncology at the San Raffaele Cancer Center in Milan, Italy. They examined the use of the drug as a treatment for HER2-positive breast cancer that had recurred locally in the body or spread to other parts of the body. HER2-positive breast cancers are typically less sensitive to standard hormonal treatments and are often more aggressive than other types.

A total of 216 patients received Avastin with a chemotherapy treatment of trastuzumab (Herceptin) and docetaxel, while 208 received the chemotherapy alone.

An investigator and an expert review committee disagreed about how much of a difference the drug made in the risk of cancer progression or death. But overall, according to investigator and independent review committee analysis, the addition of the Avastin boosted the average months of survival (without worsening of the cancer) by nearly three months, the researchers said.

Dr. Hannah M. Linden, an oncologist and associate professor of medicine at the University of Washington in Seattle, called the research "exciting."

"I am delighted that further analysis will be done to try to determine which tumors respond to each therapy, and really which tumors do not need extra treatment," Linden said. "With HER 2-positive tumors, we have a plethora of options and need to learn to be efficient in maximizing benefit to patients and minimizing toxicity."

The study is scheduled for presentation this week at the 2011 San Antonio Breast Cancer Symposium. The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The U.S. National Library of Medicine has more about breast cancer.

-- Randy Dotinga

SOURCES: Hannah M. Linden, M.D., oncologist and associate professor of medicine, University of Washington, Seattle; San Antonio Breast Cancer Symposium, news release, Dec. 7, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Revokes Approval of Avastin for Breast Cancer
2. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
3. Avastin Rejection Supported by Cancer Experts
4. FDA Panel Rejects Avastin for Breast Cancer
5. Cancer Drug Avastin Makes Inroads Against Ovarian Tumors
6. NIH study finds Avastin and Lucentis are equally effective in treating AMD
7. More Evidence Cancer Drug Avastin May Cause Harm
8. More Evidence Links Avastin to Heart Failure in Breast Cancer Patients
9. FDA Advises Against Avastin as Treatment for Breast Cancer
10. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
11. Avastin Largely Safe for Patients With Type of Advanced Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
Breaking Medicine Technology: